Jubilant Life Sciences is currently trading at Rs. 772.70, up by 18.25 points or 2.42% from its previous closing of Rs. 754.45 on the BSE.
The scrip opened at Rs. 756.00 and has touched a high and low of Rs. 774.55 and Rs. 755.95 respectively. So far 6562 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 974.00 on 23-Feb-2018 and a 52 week low of Rs. 617.45 on 19-Oct-2018.
Last one week high and low of the scrip stood at Rs. 767.05 and Rs. 715.25 respectively. The current market cap of the company is Rs. 12016.97 crore.
The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 29.37% and 19.94% respectively.
Jubilant Life Sciences’ wholly-owned subsidiary -- Jubilant Pharma (JPL) has received approval to launch an offering of unsecured bonds outside India. The Notes are proposed to be issued to institutional investors outside India and listed and quoted on the Official List of the Singapore Exchange Securities Trading.
JPL proposes to undertake meetings with one or more potential international institutional investors located in different jurisdictions. The Board of Directors of Jubilant Pharma at its meeting held on February 25, 2019 has approved the same.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: